Maui Derm Hawaii, 2024

Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials

Lebwohl Mark, Strober Bruce, Langley G. Richard, et al.

Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials

Merola F. Joseph, Conrad Curdin, Hampton Philip, et al.

Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials

Thaci Diamant, Armstrong April, Gordon B. Kenneth, et al.